Company:  VISTAGEN THERAPEUTICS, IN ... (VTGN)
Form Type:  8-K
Filing Date:  3/14/2019 
CIK:  0001411685 
Address:  343 ALLERTON AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-577-3600 
Fiscal Year:  03/31 
Last Trade
Last Trade: 
$0.61  
Change: 
0.001 (0.12%)  
Trade Time: 
09:41 AM EST  
Market Cap: 
$26.04M
Trade VTGN now with 

© 2019  
Description of Business
We are a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines to treat diseases and disorders of the central nervous system (CNS) with high unmet need. Our portfolio of three clinical-stage product candidates is currently focused on major depressive disorder (MDD), neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Our most advanced product candidate, PH94B neuroactive nasal spray, is fundamentally different from all current treatments for SAD. Developed from proprietary compounds called pherines and administered as a nasal spray, PH94B activates nasal chemosensory receptors that trigger neural circuits in the brain that suppress fear and anxiety.
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    Signatures
    EXHIBIT INDEX
  EXHIBIT 99.1
  EXHIBIT 99.2